CClinicalTrials.gg
CompletedNCT03229044Updated Jul 28, 2017

Tetranectin as a Novel Obesity-associated Adipokine for Regulating Lipid Accumulation

An observational study in Obesity and Metabolic Syndrome, sponsored by National Taiwan University Hospital. Completed. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-28.

Sponsored by National Taiwan University Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
289
Ages
20 Years and older
Sex
All
01

Study summary

Adipose tissue is strongly correlated to obesity and diabetes which are two major problems in the worldwide. Adipose tissue is involved in modulating glucose and energy metabolism locally and systemically by secreting factors, called adipocytokines. Tetranectin (TN), a novel adipocytokine, is secreted by adipose tissues. TN may regulate the glucose/energy homeostasis to affect lipid accumulation.The role of TN in adipocytes with or without TN on regulation of adipose tissue growth and lipid metabolism is valuable to be studied.

Materials and methods: Secreted proteins from human adipocyte culture medium were deciphered using 2-D polyacrylamide gel electrophoresis and determined by LC/MS with MALDI-TOF analysis of proteins. Adipose tissues were obtained from the breast of 15 women undergoing mastectomy. Serum samples from 200 normal healthy people and 54 breast cancer patients were assigned to either a lean or obese group according to the body mass index. The TN protein concentration was measured in the culture medium of stromal-vascular fraction (SVF)-derived adipocytes from healthy humans, breast cancer patients, pigs and also from 3T3-L1 cells. Associations between plasma TN and other biomarkers were assessed with Pearson's correlations and multivariable linear regression.

Read the detailed description

Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. All participants gave permission and the study was approved by the Ethics Committee of National Taiwan University Hospital as no. 9461701203.

From 2012 to 2013 in National Taiwan University Hospital, a cross-sectional sampling of 21 to 78 -year old people included women and men who were living in Taiwan. Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. Fasting serum samples were obtained from 193 randomly selected persons having health check-ups. To investigate the relationship among TN and breast cancer, fasting serum samples also obtained from 54 randomly selected breast cancer patients who were 25 to 59 years old with elected surgery for breast cancer stage 0 and 1.

02

Conditions studied

  • Obesity
  • Metabolic Syndrome

Keywords

  • adipokine, tetranectin, lipid metabolism, body mass index
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 289 is above the median of 135 across 1,283 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage.

Inclusion criteria

  1. Must be above age 20 years old.
  2. Subjects must sign the written informed consent form.
  3. Must have residual fat after surgery.
  4. Clinical diagnosis of liposuction and tumor resection.

Exclusion criteria

Exclusion Criteria:

  1. Terminal cancer.
  2. Subjects have no fat tissue after surgery.
  3. Pregnant subjects.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
289 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • BMI 18-21

    Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2

    Genetic: Tetranectin

  • BMI 33-39

    Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2

    Genetic: Tetranectin

  • BMI 25-30

    Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2

    Genetic: Tetranectin

Interventions

  • GeneticTetranectin

    Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue

06

What researchers measure

Primary outcomes

  1. Tetranectin expression measure

    Detect Tetranectin expression in adipose tissue by qPCR or Western blotting

    Time frame: through study completion, an average of 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Jaquinod M, Holtet TL, Etzerodt M, Clemmensen I, Thogersen HC, Roepstorff P. Mass spectrometric characterisation of post-translational modification and genetic variation in human tetranectin. Biol Chem. 1999 Nov;380(11):1307-14. doi: 10.1515/BC.1999.166. PubMed 10614823 ↗
  • Iba K, Durkin ME, Johnsen L, Hunziker E, Damgaard-Pedersen K, Zhang H, Engvall E, Albrechtsen R, Wewer UM. Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity. Mol Cell Biol. 2001 Nov;21(22):7817-25. doi: 10.1128/MCB.21.22.7817-7825.2001. PubMed 11604516 ↗

Individual participant data

Plan to share: Undecided — Serum samples and adipose tissue from breast cancer patients were assigned to either a lean or obese group according to the body mass index. The TN protein concentration was measured in the serum samples and culture medium of stromal-vascular fraction (SVF)-derived adipocytes from breast cancer patients,

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03229044
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Jul 25, 2017
Start date
Dec 6, 2005
Primary completion
Dec 5, 2008
Completion
Dec 5, 2008
Last update
Jul 28, 2017

Study contacts

Shih-Torng Ding, Ph D
principal investigator · National Taiwan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion